Adverse prognostic impact of TGFB1 T869C polymorphism in non-small-cell lung cancer

Figures & data

Figure 1 TGFB1 T869C polymorphism contributes to elevated serum TGF-β1 level in NSCLC.

Notes: (A) The Leu10Pro substitution resulted from TGFB1 T869C polymorphism in the signal peptide of TGF-β1 protein. (B) The 3D structure of TGF-β1 protein. (C) The serum TGF-β1 level of NSCLC patients and healthy controls was tested by ELISA. (D) The serum TGF-β1 level among NSCLC patients with different genotypes. Data are shown as mean ± SD, P-value was calculated by two-sided Student’s t-test; *P<0.05, **P<0.01, and ***P<0.001.
Abbreviations: NSCLC, non-small-cell lung cancer; 3D, three-dimensional; ELISA, enzyme-linked immunosorbent assay; aa, amino acid.

Table 1 Characteristics of the study population

Variables	Cases, n (%)	Controls, n (%)
Age (years)
≥60	133 (51.0)	49 (51.6)
<60	128 (49.0)	46 (48.4)
Gender
Male	192 (73.6)	71 (74.7)
Female	69 (26.4)	24 (25.3)
Smoking
Never	89 (34.1)	39 (41.1)
Ever	172 (65.9)	56 (58.9)

Table 2 Correlations between clinicopathological features and TGFB1 T869C genotype frequencies in 261 patients with NSCLC

Variables	Genotypic frequencies
	TT (%)	TC (%)	CC (%)	P-value
Age (years)				0.828
≥60	69 (26.4)	45 (17.3)	19 (7.3)
<60	62 (23.7)	45 (17.3)	21 (8.0)
Gender				0.133
Male	91 (34.9)	73 (28.0)	28 (10.7)
Female	40 (15.3)	17 (6.5)	12 (4.6)
Smoking				0.046
Never	54 (20.7)	23 (8.8)	12 (4.6)
Ever	77 (29.5)	67 (25.7)	28 (10.7)
Clinical stage				0.000
I	49 (18.8)	7 (2.7)	4 (1.5)
II	19 (7.3)	14 (5.4)	4 (1.5)
III	47 (18.0)	48 (18.4)	8 (3.1)
IV	16 (6.1)	21 (8.0)	24 (9.2)
Histology				0.610
Adenocarcinoma	76 (29.1)	47 (18.0)	24 (9.2)
Squamous cell	42 (16.1)	36 (13.8)	11 (4.2)
Othersa	13 (5.0)	7 (2.7)	5 (1.9)
Lymph node				0.000
Positive	71 (27.2)	73 (28.0)	32 (12.2)
Negative	60 (23.0)	17 (6.5)	8 (3.1)
Distant metastasis				0.000
Absent	115 (44.1)	69 (26.5)	16 (6.1)
Present	16 (6.1)	21 (8.0)	24 (9.2)

Notes:

a Others include large cell, undifferentiated, and mixed-cell carcinomas. P-value <0.05 as statistically significant.

Abbreviation: NSCLC, non-small-cell lung cancer.

Figure 2 Kaplan–Meier curve of overall survival according to TGFB1 T869C polymorphism in NSCLC.

Notes: (A) Survival analysis stratified by CC, TC and TT groups. (B) Survival analysis stratified by TC + CC and TT groups. P-value <0.05 was considered to be significant.
Abbreviation: NSCLC, non-small-cell lung cancer.

Figure 3 Prognostic factors in Cox proportional hazards model.

Notes: Univariate (A) and multivariable (B) analyses were performed to identify prognostic factors for NSCLC. All the bars correspond to 95% CI. Bold numbers represent P-values with significant differences.
Abbreviations: NSCLC, non-small-cell lung cancer; CI, confidence interval; HR, hazard ratio.